FcRn

FcRn. The neonatal Fc receptor is a major histocompatibility complex class I-related protein that plays a crucial role in regulating the half-life and transport of immunoglobulin G. It is expressed in a variety of tissues, including the vascular endothelium, epithelial cells, and cells of the immune system. By binding to IgG in a pH-dependent manner, it protects it from lysosomal degradation, thereby controlling systemic antibody levels and facilitating transcytosis across cellular barriers.

Structure and function

The receptor is structurally homologous to MHC class I molecules, consisting of a heavy chain non-covalently associated with beta-2 microglobulin. This heterodimeric complex binds the Fc region of IgG with high affinity at the slightly acidic pH found in endosomes, but releases it at the neutral pH of the bloodstream. This unique pH-dependent binding cycle is central to its biological functions. The interaction is highly specific for IgG, distinguishing it from other Fc receptor families like FcγRI or FcεRI. Structural studies, including those using X-ray crystallography, have detailed the precise contact residues within the CH2-CH3 domain interface of the antibody.

Expression and distribution

FcRn is widely expressed across many tissues and cell types. It is found on the surface of vascular endothelial cells throughout the body, which is critical for its systemic role in IgG protection. Key epithelial barriers expressing it include the placenta, the intestinal epithelium, the alveolar epithelium of the lungs, and the blood-brain barrier. Within the immune system, it is present on antigen-presenting cells such as dendritic cells and macrophages. Expression is also noted in hepatocytes in the liver and podocytes in the kidney. This broad distribution underscores its diverse roles in immunity and transport.

Role in IgG homeostasis

The primary physiological function is the maintenance of long serum half-life of IgG, which can extend to several weeks. Following pinocytosis, IgG molecules are internalized into acidic endosomes of endothelial cells, where they bind. The receptor diverts the bound IgG away from the lysosomal degradation pathway and recycles it back to the cell surface. Upon exposure to neutral pH, IgG is released back into circulation. This salvage pathway, first elucidated in studies of maternal antibody transfer, is essential for sustaining protective antibody titers. Disruption of this system, as seen in beta-2 microglobulin deficiency, leads to markedly reduced IgG levels.

Clinical significance

Dysregulation or manipulation of FcRn function has profound clinical implications. In autoimmune diseases like myasthenia gravis, immune thrombocytopenia, and rheumatoid arthritis, pathogenic autoantibodies of the IgG class are protected from catabolism, perpetuating disease. Conversely, some individuals with common variable immunodeficiency may have altered recycling. The pathway is also exploited by certain pathogens; for instance, Staphylococcus aureus produces Protein A, which binds IgG Fc to interfere with opsonophagocytosis. Furthermore, the receptor is a critical determinant in the pharmacokinetics of therapeutic monoclonal antibodies, influencing their dosing regimens.

Therapeutic applications

Targeting the receptor has become a major therapeutic strategy. FcRn antagonists, such as the monoclonal antibodies efgartigimod and rozanolixizumab, are approved or in development to treat autoimmune conditions by competitively inhibiting IgG binding, thereby accelerating the degradation of pathogenic antibodies. Engineering therapeutic IgG variants with enhanced affinity for FcRn at acidic pH is a strategy to extend their serum half-life, improving treatment for diseases like hemophilia. Additionally, research explores using the transcytosis pathway for oral or pulmonary delivery of biologics and for enhancing drug delivery across the blood-brain barrier for conditions like Alzheimer's disease.

Category:Immunology Category:Proteins